{
    "clinical_study": {
        "@rank": "31584", 
        "acronym": "Claprum", 
        "arm_group": [
            {
                "arm_group_label": "Clarithromycin", 
                "arm_group_type": "Active Comparator", 
                "description": "Fist group treated with clarithromycin which is include 10 days application."
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Second group treated with salin as same as amount of clarithromycine volume"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine of clarithromycin effect on developing of\n      bronchopulmonary dysplasia  in preterm babies."
        }, 
        "brief_title": "Clarithromycin Prophylaxis in Preterm Infants Colonisation With Ureaplasma Urealyticum and Mycoplasma Hominis", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Bronchopulmonary Dysplasia", 
        "condition_browse": {
            "mesh_term": "Bronchopulmonary Dysplasia"
        }, 
        "detailed_description": {
            "textblock": "The investigators planned that clarithromycin treatment in preterm babies who are under 1250\n      grams birth weight.\n\n      The investigators aimed with this treatment, the  bronchopulmonary dysplasia rate of preterm\n      babies may decrease."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  all infant must be under 1250 gram birth weight\n\n        Exclusion Criteria:\n\n          -  Major congenital anomaly,\n\n          -  CardiaC abnormality,\n\n          -  without inform consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "2 Days", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 22, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01652118", 
            "org_study_id": "05059079727"
        }, 
        "intervention": [
            {
                "arm_group_label": "Clarithromycin", 
                "intervention_name": "clarithromycin treatment for prophylaxis of bronchopulmonary dysplasia", 
                "intervention_type": "Drug", 
                "other_name": "Claprum"
            }, 
            {
                "arm_group_label": "placebo", 
                "intervention_name": "Saline", 
                "intervention_type": "Drug", 
                "other_name": "saline"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Clarithromycin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "bronchopulmonary dysplasia", 
            "clarithromycin", 
            "preterm babies"
        ], 
        "lastchanged_date": "July 26, 2012", 
        "location": {
            "contact": {
                "last_name": "Sad\u0131k Yurttutan, M.D", 
                "phone": "0905059079727"
            }, 
            "contact_backup": {
                "email": "femrecan@gmail.com", 
                "last_name": "Fuat Emre Canpolat, M.D."
            }, 
            "facility": {
                "address": {
                    "city": "Ankara", 
                    "country": "Turkey", 
                    "state": "Middle Anatolia", 
                    "zip": "06600"
                }, 
                "name": "Zekai Tahir Burak Maternity Teaching Hospital"
            }, 
            "investigator": {
                "last_name": "Sad\u0131k Yurttutan, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Turkey"
        }, 
        "number_of_arms": "2", 
        "official_title": "Prophylaxis of Bronchopulmonary Dysplasia With Clarithromycin", 
        "overall_contact": {
            "email": "sdkyurttutan@gmail.com", 
            "last_name": "Sad\u0131k Yurttutan, M.D", 
            "phone": "0905059079727"
        }, 
        "overall_contact_backup": {
            "email": "femrecan@gmail.com", 
            "last_name": "Fuat Emre Canpolat, M.D."
        }, 
        "overall_official": {
            "affiliation": "Zekai Tahir Burak Maternity and Teaching Hospital", 
            "last_name": "Ugur Dilmen, Prof. Dr.", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Turkey: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "On the 28. day of birth, The investigator will determine the baby whether has developed bronchopulmonary dysplasia", 
            "measure": "Bronchopulmonary dysplasia", 
            "safety_issue": "Yes", 
            "time_frame": "28. day of birth"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01652118"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Zekai Tahir Burak Maternity and Teaching Hospital", 
            "investigator_full_name": "Sadik Yurttutan", 
            "investigator_title": "Fellowship of neonatology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "During to hospitalisation the investigator will determine and record some co-morbidities of BPD such as intracranial hemorrhage, necrotizing enterocolitis, patent ductus arteriosus rates.From date of randomization until the end of the hospitalisation up to the 3 months of life.", 
            "measure": "Overall survival", 
            "safety_issue": "Yes", 
            "time_frame": "Participants will be followed for the duration of hospital stay, an expected average of postnatal 40 weeks"
        }, 
        "source": "Zekai Tahir Burak Maternity and Teaching Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Zekai Tahir Burak Maternity and Teaching Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "July 2012"
    }
}